Posted inDermatology news
Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON
Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.